PPARα Is Essential for Microparticle-Induced Differentiation of Mouse Bone Marrow-Derived Endothelial Progenitor Cells and Angiogenesis by Benameur, Tarek et al.
PPARa Is Essential for Microparticle-Induced
Differentiation of Mouse Bone Marrow-Derived
Endothelial Progenitor Cells and Angiogenesis
Tarek Benameur
1,2,3, Simon Tual-Chalot
1,2,3, Ramaroson Andriantsitohaina
1,2,3,M a r ı ´a Carmen
Martı ´nez
1,2,3*
1CNRS, UMR 6214, Angers, France, 2INSERM, U771, Angers, France, 3Faculte ´ de Me ´decine, Universite ´ d’Angers, Angers, France
Abstract
Background: Bone marrow-derived endothelial progenitor cells (EPCs) are critical for neovascularization. We hypothesized
that microparticles (MPs), small fragments generated from the plasma membrane, can activate angiogenic programming of
EPCs.
Methodology/Principal Findings: We studied the effects of MPs obtained from wild type (MPs
PPARa+/+) and knock-out
(MPs
PPARa2/2) mice on EPC differentiation and angiogenesis. Bone marrow-derived cells were isolated from WT or KO mice
and were cultured in the presence of MPs
PPARa+/+ or MPs
PPARa2/2 obtained from blood of mice. Only MPs
PPARa+/+ harboring
PPAR
a significantly increased EPC, but not monocytic, differentiation. Bone marrow-derived cells treated with MPs
PPARa+/+
displayed increased expression of pro-angiogenic genes and increased in vivo angiogenesis. MPs
PPARa+/+ increased capillary-
like tube formation of endothelial cells that was associated with enhanced expressions of endothelial cell-specific markers.
Finally, the effects of MPs
PPARa+/+ were mediated by NF-kB-dependent mechanisms.
Conclusions/Significance: Our results underscore the obligatory role of PPARa carried by MPs for EPC differentiation and
angiogenesis. PPARa-NF-kB-Akt pathways may play a pivotal stimulatory role for neovascularization, which may, at least in
part, be mediated by bone marrow-derived EPCs. Improvement of EPC differentiation may represent a useful strategy
during reparative neovascularization.
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Introduction
Bone marrow-derived endothelial progenitor cells (EPCs)
possess the capacity to proliferate, migrate, and differentiate into
endothelial lineage cells [1]. EPCs are mobilized from bone
marrow into the circulation during vascular injury, and then home
to the site of neovascularization and thereby contribute to
postnatal neovascularization [2–4]. Moreover, decreased levels of
EPCs correlate with subsequent increases in cardiovascular events
suggesting that EPCs are important predictors for cardiovascular
mortality and morbidity [5,6]. It has also been proposed that other
populations of bone marrow-derived cells that are phenotypically
different from EPCs can also be recruited to the injured
endothelium and contribute to the regeneration of the endothe-
lium [7]. Characterization of these cells indicates that they mainly
express hematopoietic lineage markers such as CD11b, CD14 and
CD45 [8], whereas EPCs express CD31, CD106, and Flk-1 [9].
One potential limitation for the use of autologous bone marrow
EPCs for therapeutic vasculogenesis is the decline in the number
and function of progenitor cells in patients with coronary artery
disease [10], diabetes [11], metabolic syndrome [12] and severe
heart failure [13]. Therefore, enhancing EPC differentiation and
homing towards sites of injury will likely improve efficiency of cell
therapy; this approach is a subject of intense investigation.
Emerging evidence indicates that PPARa, a member of the
nuclear hormone receptor superfamily activated by ligands and
several fatty acids [14], improves nitric oxide (NO)-mediated
vasodilatation in conductance and resistance vessels and also
protects against myocardial ischemic injury [15].Recent reports
suggest that stimulation of PPARa, but not PPARb or PPARc,
enhances cardiac progenitor differentiation through the involve-
ment of NADPH oxidase activity [16,17] and that activation of
PPARa induces neovascularization through a VEGF-dependent
mechanism [18,19]. Collectively these studies suggest that
stimulation of PPARa may stimulate cell differentiation.
The role of cell-to-cell communication involving membrane
fragments such as microparticles (MPs) [20,21] during neovascu-
larization is unknown. MPs are small vesicles released from the
plasma membrane of stimulated or apoptotic cells; their protein
composition is not completely elucidated, but it differs in function
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[22]. Importantly, MPs can transfer receptors and organelles
between cells and deliver mRNA and proteins into cells [20].
Thus, MPs can be considered as real vectors of biological messages
such as induction of angiogenesis or differentiation since
endothelial, platelet or lymphocytic MPs can modulate in vitro
and in vivo angiogenic properties of EPCs and ECs [23–26].
However, the mechanism(s) by which circulating MPs modulate
angiogenesis have not elucidated. Because PPARs can be harbored
by MPs [27], we hypothesized that the effects of circulating MPs
on EPC differentiation may be mediated, at least in part, by the
PPARa pathway. Therefore, the aim of this study was to
determine whether circulating MPs induce bone marrow-derived
cell differentiation towards an endothelial lineage and increase
angiogenic-related properties of these cells and ECs.
Results
The number and origin of circulating MPs does not differ
between wild type (WT) and PPARa null mice
Flow cytometry analysis of circulating MPs (Figure 1A and B)
showed that the total number of circulating MPs was not
significantly different between PPARa null mice (20566
360 MPs/mL plasma) and their corresponding WT littermates
(16786417 MPs/mL plasma), indicating that PPARa deletion
did not affect the circulating levels of MPs (Figure 1C). These
MP concentrations were used for further experiments. There
was also no significant differences in the cellular origins of MPs
between the two groups of mice (Figure 1C) with only MPs
from PPARa WT (MPs
PPARa+/+) expressing PPARa receptors
(Figure 1D).
Figure 1. Phenotypic characterization of circulating MP levels in PPARa+/+ mice compared to PPARa2/2 mice. Circulating MPs from
PPARa+/+ (A) and PPARa2/2 (B) mice and Flowcount beads (Beads region, 10 mm diameter) are visualized in a side scatter (SS)/forward scatter (FS)
logarithmic representation. MPs are defined as events with size 0.1 to 1 mm gated in the ‘‘MPs’’ window. (C) Different populations of MPs derived
from platelets, leukocytes, endothelial cells, erythrocytes, procoagulant MPs and MPs from progenitor cells. There was no significant difference in
circulating MP origins between PPARa2/2 and their WT littermate mice. (D) Western blot indicates that MPs isolated from PPARa WT mice blood
harboured PPARa, while those isolated from PPARa2/2 mice blood did not. Figures are representative of at least 5 independent experiments for
each condition.
doi:10.1371/journal.pone.0012392.g001
MPs-PPAR & Endothelial Cells
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PPARa+/+, but not MPs
PPARa2/2, increase
the differentiation of bone marrow-derived cells towards
the EPC lineage
Phenotypic characterization of bone marrow-derived cells using
multiple markers indicates that, at day 7, the presence of
populations ofbone marrow-derived cellsdisplayingdoublelabeling
of Sca-1
+/CD31
+, Sca-1
+/CD45
+, Sca-1
+/CD14
+ and F4/80
+/
CD31
+ whose levels were enhanced compared to those at day 0
(Figure S1).Itshouldbenotedthat the percentagesofbone marrow-
derived cells expressing Sca-1
+/Flk-1
+ and CD133
+/Flk-1
+ were
not significantly different at day 0 and 7. This characterization
indicates that, at day 7, bone marrow-derived cells are mainly cells
expressing monocytic and endothelial markers; and moreover that
the EPC subpopulation belongs to the so-called ‘‘early EPCs’’.
To investigate the effects of PPARa carried by MPs on in vitro bone
marrow-derived cell differentiation, circulating MPs isolated from
PPARa-deficient or WT mice were added to adherent bone marrow-
derived cellsfromWTmice.Thereafter,EPCswere identified byDil-
Acetyl-LDL-uptake with concomitant lectin binding, as previously
described [28], and doubleexpression of Sca-1 and Flk-1 determined.
After 7 days, isolated bone marrow-derived cells cultured in the
presence of MPs
PPARa+/+ displayed enhanced adhesion but with no
changes in cell proliferation (data not shown). At day 7, confocal
microscopy characterization of adherent cells incubated with
MPs
PPARa+/+, but not with MPs
PPARa2/2,a l s od e m o n s t r a t e d
increased Dil-ac-LDL/lectin uptake typical for endothelial lineage
(Figure 2A). As illustrated in Figure 2B, quantification indicates that
only MPs
PPARa+/+ significantly increased the number of double-
positive (Dil-Ac-LDL
+/lectin
+) cells. Similar results were obtained by
flow cytometry, revealing double-positive staining with Sca-1/Flk-1.
Indeed, MPs
PPARa+/+ increased the number of differentiated EPC-
like attaching cells by 36% (Figure 2C). In contrast, the number of
Sca-1
+Flk-1
+ cells were significantly lower in EPCs treated with
MPs
PPARa2/2 when compared with non-treated EPCs (Figure 2C).
In addition, MPs
PPARa+/+ had no effect on the number of cells
expressing both F4/80 and CD31 markers whereas the number of
F4/80
+CD31
+ cells treated with MPs
PPARa2/2 were significantly
reduced (Figure 2D).
Pharmacological PPARa activation induces EPC
differentiation
To evaluate the presence of a functional PPARa pathway in
bone marrow-derived cells and also whether direct activation of
PPARa leads to EPC differentiation, we first analyzed PPARa
expression in bone marrow-derived cells and secondly, we used a
selective PPARa agonist, WY-14643 (5 mM) to stimulate EPC
differentiation of cells isolated from WT mice. As shown by
Western blot, PPARa was expressed on bone marrow-derived cells
at day 7 of culture (Figure S2A) and that PPARa levels were not
modified in bone marrow-derived cells after incubation with
Figure 2. MPs
PPARa+/+ treatment increases the number of EPC undergoing in vitro differentiation. (A) Confocal microscopy
characterization of mice bone marrow-derived EPC differentiation: cells were incubated in the absence or in the presence of either MPs
PPARa+/+ or
MPs
PPARa2/2. After 7 days in culture, cells with endothelial phenotype were characterized as adherent cells with double-positive staining for Dil-
acetylated-LDL (red) and lectin (green). Nuclei were counterstained with DAPI (blue). (B) Quantification of Dil-acetylated-LDL- and lectin-positive cells
derived from bone marrow in the absence or in the presence of either MPs
PPARa+/+ or MPs
PPARa2/2. Histogram showing the effects of MPs either from
PPARa+/+ or PPARa2/2 mice, on the differentiation of EPCs. (C) Flow cytometric characterization of EPC differentiation. Cells with double-positive
staining for Sca-1
+/Flk-1
+ were identified as differentiating EPCs. (D) Flow cytometric characterization of macrophage differentiation. Cells with
double-positive staining for F4/80
+/CD311
+ were identified as macrophages. Data are shown as mean values6SEM of at least 3 independent
experiments for each condition. *P,0.05, **P,0.01, ***P,0.001 vs in the absence of MPs (control); #P,0.05, ##P,0.01 vs in the presence of
MPs
PPARa+/+.
doi:10.1371/journal.pone.0012392.g002
MPs-PPAR & Endothelial Cells
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PPARa+/+ (Figure S2A), suggesting that PPARa transfer
between MPs and bone marrow-derived cells did not take place.
Interestingly, the PPARa agonist significantly increased (,42%)
EPC differentiation from WT but not from PPARa-null mice as
assessed by Sca-1
+/Flk-1
+ staining (Figure S2B and S2C). In
addition, when bone marrow-derived cells from PPARa-null mice
were treated with MPs from WT mice, no changes in EPC
differentiation were observed (Figure S2D). Altogether, these
results demonstrated the presence of functional PPARa receptors
on bone marrow-derived cells from WT mice that induce
differentiation and that it was unlikely that PPARa protein was
transferred from MPs to bone marrow-derived cells.
MPs
PPARa+/+-induced EPC differentiation is associated
with up-regulation of pro-angiogenic factor mRNA levels
To confirm and extend the results obtained by immunofluores-
cence and flow cytometry, we further analyzed the expression of
differentiation marker genes profiles by q-PCR. Mice endothelial
markers and angiogenic gene expression were analyzed using a
panel of 52 transcripts (Table S1). The data in Figure 3, which was
obtained from cultured bone marrow-derived cells, shows that
MPs
PPARa+/+ enhances the expression of pro-angiogenic factors
such as VEGF A, SDF-1, and angiopoietin-2, while the expression
of thrombospondin-1 (TSP-1), which has a potent anti-angiogenic
activity, was significantly reduced. In addition, mRNA levels of
endothelial markers such as VE-cadherin, PECAM-1 and ICAM-
1 were increased. Any significant changes of mRNA levels of pro-
angiogenic factors and endothelial markers were observed when
bone marrow-derived cells were treated with MPs
PPARa2/2.
MPs
PPARa+/+ enhance EC-specific marker expression and
Akt activity
We investigated the molecular mechanisms underlying the
effects of MPs on EPC differentiation. To further confirm the
Figure 3. MPs
PPARa+/+ upregulate mRNA levels of pro-angiogenic factors and SDF-1 in differentiating bone marrow-derived cells.
Quantitative RT-PCR analysis of pro-angiogenic factors in cultured EPCs demonstrated that MPs
PPARa+/+, but not MPs
PPARa2/2, increased mRNA levels
of VE-cadherin, ICAM-1, Ang-2, VEGF-A, PECAM-1 and SDF-1. TSP-1 mRNA level was down-regulated in MPs
PPARa+/+-treated EPCs whereas up-
regulated in MPs
PPARa2/2-treated EPCs. *P,0.05, **P,0.01 vs in the absence of MPs; #P,0.05, ##P,0.01 vs in the presence of MPs
PPARa+/+. Figures
are representative of at least 3 independent experiments for each condition.
doi:10.1371/journal.pone.0012392.g003
MPs-PPAR & Endothelial Cells
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differentiation at day 7 of growth, we examined the protein
expression levels in cellular extracts of pro-angiogenic and EC
specific markers and Akt activity in the bone marrow-derived cells
(Figure 4). Consistent with the results obtained by q-PCR, Western
blot analysis revealed that MPs
PPARa+/+ significantly enhanced VEGF
A but not its receptor FLT-1. Besides, ICAM-1 but not eNOS
expression was significantly enhanced upon MPs
PPARa+/+ stimulation.
In contrast, MPs isolated from PPAR
a-deficient mice significantly
decreased the expression of eNOS, VEGF and FLT-1. To
demonstrate whether Akt signalling mediates EPC differentiation,
bone marrow-derived cells from PPARa WT mice were incubated in
the absence or presence of either MPs
PPARa+/+ or MPs
PPARa2/2,a n d
Akt phosphorylation on Ser 473 indicative for Akt activity was detected
by Western blot analysis. MPs
PPARa+/+,b u tn o tM P s
PPARa2/2,
stimulated Akt phosphorylation indicating an increased activity of
Akt in differentiating bone marrow-derived cells (Figure 4).
MPs
PPARa+/+ favor in vitro capillary-like structure
formation of ECs
To examine the effects of MPs on the capacity of ECs to form
capillary-like structure, ECs were seeded on MatrigelH for
24 hours in the absence or presence of either MPs
PPARa+/+ or
MPs
PPARa2/2. In the absence of stimulation, ECs from both
PPARa WT and KO mice form capillary-like structures
suggesting that deletion of PPARa did not affect the angiogenic
capacity of ECs (Figure S3A and S3B). Interestingly,
MPs
PPARa+/+ induced significant increases in the number of
capillary-like structures (,55%) relative to untreated ECs from
PPARa WT mice (Figure 5A and 5B). To determine whether
PPARa accounts for the effects induced by MPs
PPARa+/+,w e
assessed the effects of PPARa deletion on MP-induced capillary
formation. Capillary formation was absent abolished by
MPs
PPARa2/2 (Figure 5A), suggesting that PPARa harbored
by MPs is essential for MP-induced capillary-like structure
formation of ECs.
NF-kB pathway is involved in MP-induced EPC
differentiation and in vitro EC angiogenesis
NF-kB is a transcription factor that is complexed with I-kBa
and b in the cytoplasm, which are selectively phosphorylated,
ubiquinated, and degraded, leading to NF-kB translocation.
Phosphorylation of I-kBa results in the activation of NF-kB and
so allows its translocation to the nucleus.
Western blot analysis of bone marrow-derived cell extracts
demonstrated that MPs
PPARa+/+, but not MPs
PPARa2/2, signifi-
cantly enhanced I-kBa phosphorylation on Ser32/36 (Figure 6A),
highlighting the activation of NF-kB signaling. To elucidate
Figure 4. MPs
PPARa+/+ enhance endothelial-specific marker expression and Akt activation in bone marrow-derived cells. Western blot
analysis of EC-markers expression associated with EPC differentiation and Akt phosphorylation. While MPs
PPARa+/+ enhanced ICAM-1 and VEGF
expressions, MPs
PPARa2/2 significantly attenuated expressions of VEGF, eNOS and FLT-1. Protein expression was normalized by b-actin.
Representative Western blots of Akt expression and phosphorylation on its activator site (Ser 473) in EPCs. Histogram showing the increase of P-Akt
(ser473)/Akt ratio induced by MPs
PPARa+/+ in EPCs. *P,0.05, **P,0.01, ***P,0.001 vs in the absence of MPs; #P,0.05, ##P,0.01 vs in the presence
of MPs
PPARa+/+. Figures are representative of at least 3 independent experiments for each condition.
doi:10.1371/journal.pone.0012392.g004
MPs-PPAR & Endothelial Cells
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differentiation induced by MPs
PPARa+/+, we used BAY11-7082
(5 mM), an inhibitor of I-kBa phosphorylation. As shown in
Figure 6B, MPs
PPARa+/+ significantly increase the number of
double-positive EPCs for Sca-1
+/Flk-1
+ staining. These effects
were prevented by incubation with BAY11-7082, suggesting a
potential role of the NF-kB pathway in EPC differentiation
induced by MPs
PPARa+/+. In addition, the weak decrease in EPC
differentiation induced by MPs
PPARa2/2 was not modified by
BAY11-7082 (Figure 6B) suggesting that NF-kB pathway is not
implicated in the effects of MPs
PPARa2/2.
In another set of experiments, aortic ECs isolated from WT
mice were preincubated with BAY11-7082 for 30 minutes, and
then later incubated for 24 hours in the absence or presence of
MPs
PPARa+/+. As observed during EPC differentiation experi-
ments, BAY11-7082 also abolished MPs
PPARa+/+-induced capil-
lary network formation of mature ECs on MatrigelH (Figure 6C),
suggesting the involvement of the NF-kB pathway in in vitro effects
of MPs
PPARa+/+ on EC-mediated angiogenesis.
MPs
PPARa+/+ promote in vivo bone marrow-derived
cell-mediated angiogenesis
Finally, to investigate the effects of MPs on the formation of
the new vessels, in vivo angiogenesis was studied by using
MatrigelH plug assay. At day 7, a blush of vessel proliferation was
clearly observed in plugs from mice injected with bone marrow-
derived cells treated with MPs
PPARa+/+, but not with
MPs
PPARa2/2 (Figure 7A). These effects were further quantified
by measuring the hemoglobin content of the plugs. Vasculari-
zation of the plugs was significantly enhanced (,25%) in mice
injected with bone marrow-derived cells treated with
MPs
PPARa+/+ when compared with those untreated or treated
with MPs
PPARa2/2 (Figure 7B). No further effect was observed
at day 15 (not shown). Conversely, when compared with control,
hemoglobin content of new-formed blood vessels was signifi-
cantly reduced (,20%) in plugs mixed with MPs
PPARa2/2-
treated bone marrow-derived cells. Vascularization of the plugs
induced by MPs
PPARa+/+ was abolished when bone marrow-
derived cells were pre-treated with an inhibitor of NF-kB
pathway, suggesting a key role of NF-kB activation in the effects
evoked by MPs
PPARa+/+ (Figure 7A and 7B).
Discussion
Our study demonstrates for the first time that PPARa harbored
by MPs mediate the functionality and the differentiation of bone
marrow-derived EPCs. The major findings of our study are that
MPs
PPARa+/+: (i) increase EPC differentiation and EC marker
expression, but not those of macrophage differentiation; (ii)
enhances EPC differentiation that is mediated, at least in part,
by PPARa-NF-kB and Akt pathways; (iii) modulate in vitro
angiogenic-related properties of ECs; and (iv) stimulate in vivo
bone marrow-derived cell-associated neovascularization. Altogeth-
er, these findings provide a novel mechanism underlying EPC
differentiation and angiogenesis.
Figure 5. MPs
PPARa+/+ enhance EC capacity to induce capillary like-structure formation on MatrigelH. (A) Phase contrast micrographs of
aortic ECs isolated from WT mice. ECs were incubated for 24 hours in the absence or either in the presence of MPs
PPARa+/+ or MPs
PPARa2/2.( B)
Quantification of capillary number revealed that MPs
PPARa+/+ increased significantly the formation of tubular like-structures of ECs on MatrigelH.
Organization of ECs into capillary-like structures on MatrigelH was markedly inhibited when ECs were treated with PPARa deficient MPs. *P,0.05.
Figures are representative of at least 3 independent experiments for each condition.
doi:10.1371/journal.pone.0012392.g005
MPs-PPAR & Endothelial Cells
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particular,EPCsandmacrophagesplaycriticalrolesinangiogenesis
and potentially help to repair injured endothelium [29,30]. In this
study, we show that, after 7 days of culture, bone marrow-derived
cells are mainly EPCs (Sca-1
+CD31
+) and monocyte/macrophages
(Sca-1
+CD14
+ and F4/80
+CD31
+), but after MPs
PPARa+/+ treat-
ment, EPC but not macrophage differentiation was observed.
Several studies confirm that MPs favor angiogenesis. Whereas
platelet-derived MPs promote angiogenesis through ERK pathway
activation [25], endothelial-derived MPs increase capillary-like
structure formation via plasminogen generation [23]. We recently
reported that MPs from apoptotic/activated lymphocytes evoke
angiogenesis through the up-regulation of adhesion and pro-
angiogenic factors [26]. However, no data are available concern-
ing circulating MPs. Here, we show that circulating MPs from WT
mice favor both in vitro and in vivo angiogenesis through the
modulation of EPC differentiation and angiogenic function, while
MPs
PPARa2/2 decreased both EPC and macrophage differentia-
tions. We cannot rule out the possibility that PPARa deletion can
induce other cellular modifications, as previously shown in T cells
from PPARa KO mice [31,32]. Although the mechanisms by
which MPs
PPARa+/+ induces both EPC differentiation and
neovascularization are not completely elucidated, we demonstrat-
ed that effects evoked by MPs
PPARa+/+ involve NF-kB signaling
that was associated with Akt activation. Moreover, PPARa is
not transferred from MPs into bone marrow-derived cells since
PPARa expression is not enhanced in these cells after treatment
with MPs
PPARa+/+. On the other hand, PPARa is expressed
and functional in bone marrow-derived cells, suggesting that
lipids harbored by MPs
PPARa+/+, but not those carried by
MPs
PPARa2/2, may act as endogenous ligands. In agreement
with previous studies [33,34], it is possible that mRNA or
miRNA delivery from MPs
PPARa+/+ to target cells (in this case
bone marrow-derived cells or ECs) may be responsible for changes
of their phenotype. In this context, it has been described that MPs
from EPCs may activate angiogenic program in ECs [34]. Further
experiments are necessary to determine the molecular mechanism
by which MPs transfer their message.
Figure 6. MPs
PPARa+/+-induced EPC differentiation and in vitro angiogenesis of mature ECs involve NF-kB pathway activation. (A)
Western blot showing that MPs
PPARa+/+ induced I-kB phosphorylation on activator sites (Ser32/36) in EPCs, indicating that NF-kB pathway is activated.
No change in I-kBa phosphorylation was observed in MPs
PPARa2/2-treated EPCs. *P,0.05 vs in the absence of MPs. (B) Flow cytometric
characterization of EPC differentiation showed that the EPC pretreatment with BAY11-7082 (5 mM) was able to abolish the effect of MPs
PPARa+/+ on
EPC differentiation. However, the decrease in EPC differentiation induced by MPs
PPARa2/2 was insensitive to BAY11-7082. **P,0.01, ***P,0.001,
*P,0.05 vs in the absence of MPs; ##P,0.01, #P,0.05 vs in the presence of MPs
PPARa+/+.( C) Formation of MP-induced capillary like-structures of
ECs on MatrigelH was markedly inhibited in pretreated ECs with NF-kB pathway inhibitor BAY11-7082 (5 mM). The results indicate the involvement of
NF-kB in both MPs
PPARa+/+-induced EPC differentiation and EC-mediated angiogenesis. Figures are representative of at least 3 independent
experiments for each condition.
doi:10.1371/journal.pone.0012392.g006
MPs-PPAR & Endothelial Cells
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murine stem cells towards cardiac cells [16,17] while PPARa
activators induce keratinocyte differentiation [35] and phenotypic
modulation of rat oval cells toward the hepatocyte lineage [36].
Biscetti and coworkers [19] recently reported that iloprost-induced
angiogenesis and VEGF up-regulation are dependent on the
presence and proper function of PPARa gene. Besides, PPARc
agonists favorably modulated bone marrow-derived progenitor
cells to promote endothelial lineage [37]. Our findings demon-
strate that the PPARa gene is necessary for MPs to develop pro-
angiogenic activity since circulating MPs form PPARa deficient
mice did not induce either EPC differentiation, in vivo neovascu-
larization or in vitro EC angiogenesis. In addition, the selective
pharmacological PPARa agonist WY-14643 evoked EPC differ-
entiation in bone marrow-derived cells from WT PPARa mice,
but not in those derived from KO PPARa mice, suggesting that
PPARa activation accounts for pro-angiogenic effects on EPCs.
To elucidate the potential molecular mechanisms underlying
EPC differentiation and pro-angiogenic properties of MPs
harboring PPARa, we evaluated the expression of pro-angiogenic
factors at the mRNA level in ex vivo expanded bone marrow-
derived cells pretreated with MPs
PPARa+/+ or MPs
PPARa2/2.A
significant increase of mRNA levels of pro-angiogenic factors, such
as VEGF A, Ang-2 and SDF-1 was observed in bone marrow-
derived cells treated with MPs
PPARa+/+, suggesting that MPs from
PPARa mice may be involved in the enhanced homing ability of
EPCs and in their pro-angiogenic abilities. Since SDF-1
pretreatment during EPC expansion stimulates EPC adhesion
and increases the efficiency of cell therapy for ischemic vascular
diseases, increases EPC number and recruitment of bone marrow-
derived EPCs into site of ischemia [38], one can advance the
hypothesis that MPs
PPARa+/+ can be used as an expansion agent of
EPCs. In addition, expressions of EC markers such as VE-
cadherin, PECAM-1, and ICAM-1 were increased, indicating that
MPs
PPARa+/+ evoke differentiation of bone marrow-derived cells
towards an endothelial lineage. In contrast, TSP-1 which possesses
potent anti-angiogenic activity [39] was down-regulated in bone
marrow-derived cells treated by MPs
PPARa+/+ and conversely up-
regulated in pretreated bone marrow-derived cells with
MPs
PPARa2/2. These results emphasize the key role of PPARa
in modulating angiogenic potential of bone marrow-derived cells.
Supporting the results obtained with bone marrow-derived cells,
MPs
PPARa+/+ also significantly enhanced the expression of the pro-
angiogenic factor VEGF and EC marker ICAM-1, whereas
Figure 7. MPs
PPARa+/+ promote in vivo bone marrow-derived cell-mediated angiogenesis. (A) MPs
PPARa+/+-, in the absence or in the
presence of BAY11-7082 (5 mM), or MPs
PPARa2/2-pretreated bone marrow-derived cells were detached, mixed with MatrigelH and b-FGF and injected
subcutaneously into WT mice. At day 7, an enhanced neovascularization was observed in plugs containing bone marrow-derived cells pretreated
with MPs
PPARa+/+. (B) Quantitative measurement of hemoglobin was reported as arbitray units/weight of plugs. Hemoglobin content was increased in
plugs containing MPs
PPARa+/+-treated bone marrow-derived cells and decreased in those containing MPs
PPARa+/+-treated bone marrow-derived cells in
the presence of BAY11-7082 or in those containing MPs
PPARa2/2-treated bone marrow-derived cells. *P,0.05 vs in the absence of MPs (CTL).
#P,0.05 vs in presence of MPs
PPARa+/+. Figures are representative of at least 3 independent experiments for each condition.
doi:10.1371/journal.pone.0012392.g007
MPs-PPAR & Endothelial Cells
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decreased in bone marrow-derived cells treated with
MPs
PPARa2/2. These data are in accordance with those recently
reported by Biscetti et al [18] showing that PPARa activation
evokes angiogenesis through VEGF up-regulation. Collectively,
these results indicate that MPs
PPARa+/+ are able to promote the
angiogenic program of both EPCs and ECs so as to enhance their
proangiogenic properties. However, it remains to be determined
whether MPs
PPARa+/+ act directly on bone marrow-derived cells to
induce EPC differentiation and pro-angiogenic factor release (i.e.
VEGF) or whether bone marrow-derived cells play a paracrine
angiogenic role. In this respect, it has been shown the essential
paracrine role of recruited bone marrow-derived circulating cells
occurs by secreting pro-angiogenic factors rather than serving as
endothelial progenitors in an adult model of neovascularization
[29]. These authors have shown that SDF-1 secreted by
perivascular cells in response to VEGF is responsible for
positioning of bone marrow-derived circulating cells near to blood
vessels. In this study, we show that MPs
PPARa+/+ enhances both
VEGF and SDF-1 mRNA, suggesting that similar mechanisms
may occur.
The anti-inflammatory actions of PPARs have been largely
described to inhibition of the NF-kB pathway [40,41]. Surprisingly,
in our study the effects of MPs
PPARa+/+ on EPC differentiation and
EC angiogenesis are sensitive to NF-kB inhibition. Furthermore,
MPs
PPARa+/+ effects were associated with increased phosphoryla-
tion of I-kBa (Ser32/36) in bone marrow-derived cells. These
findings suggest a positive regulation of NF-kB pathway by PPARa,
as described in other studies [42]. In this context, PPARs have been
recently reported to be involved in neural stem cells (NSC)
acquisition of a specific fate, and the control of NSC proliferation,
migration and differentiation through NF-kB pathway [43]. A
similar signaling through PPARa significantly may contribute to
EPC differentiation via stimulation of NF-kB pathway.
The Akt pathway plays a central role in the functioning of
mature ECs. Thus, activation of Akt promotes endothelial cell
survival by inhibiting apoptosis and is involved in EPC
differentiation [44]. Our study not only extends these findings
by demonstrating that Akt activation is associated with EPC
differentiation, but also suggests Akt as a target for MPs
PPARa+/+ in
modulating EPC differentiation and functions. On the basis of
these findings, it is possible that one of the mechanisms that
mediates EPC differentiation induced by MPs
PPARa+/+ is the
crosstalk between PPARa-NF-kB and Akt pathways.
Finally, to further validate our obtained data concerning the
effects of MPs
PPARa+/+ on in vitro EPC differentiation, we
investigated the in vivo effects of untreated or MP-treated bone
marrow-derived cells on neovascularization. MPs
PPARa+/+-treated
bone marrow-derived cells enhanced the formation of new vessels
as assessed by increased hemoglobin content in MatrigelH plugs;
these effects were attenuated by inhibition of the NF-kB pathway.
These findings demonstrate that isolated bone marrow-derived
cells expanded by in vitro MP treatment are able to generate in vivo
functional vessels and confirm our results obtained in vitro.
In conclusion, the results of this study confirm the pro-
angiogenic ability of circulating MPs harboring PPARa, which
are able to induce in vitro EPC differentiation and angiogenesis
through the NF-kB pathway. Therefore, MP treatment may
significantly contribute to EPC differentiation and stimulation of
neovascularization following ischemic injury. The PPARa-NF-kB-
Akt pathways may play a pivotal stimulatory role in neovascular-
ization, which is, at least in part, mediated through bone marrow-
derived EPCs. Improvement of EPC differentiation may greatly
aid reparative neovascularization.
Materials and Methods
Circulating MP isolation
All animal studies were carried out using approved institutional
protocols and were conformed the Guide for the Care and Use of
Laboratory Animals published by US National Institutes of Health
(NIH Publication No. 85-23, revised 1996). Mice (6 to 8 week old)
were anesthetized by isofluorane for all procedures. Circulating
MPs were isolated from venous citrated blood collected from
PPARa null (KO) and corresponding wild-type (WT). PPARa KO
mice were generated by the group of Gonzalez, as previously
described [45]. Briefly, blood was centrifuged at 1,900 g for 3
minutes and platelet-rich plasma was separated from whole blood.
Then, platelet-rich plasma was centrifuged at 5,000 g for 4
minutes to obtain platelet-free plasma (PFP). Sixty mL of PFP were
frozen and stored at 280uC until subsequent use. In order to pellet
MPs for in vitro and in vivo studies, circulating MPs were
concentrated from PFP by three series of centrifugations at
21,000 g for 45 minutes and resuspended in 0.9% saline salt
solution and stored at 4uC until subsequent use. The physiological
circulating concentration of mice MPs was used in all experiments.
Washing medium for the last supernatant was used as control.
Characterization of MP phenotype
Membrane MP subpopulations were discriminated in PFP
according the expression of membrane-specific antigens. Pheno-
type of endothelial MPs was performed using anti-CD54 labeling,
characterization of platelet, leukocyte and erythrocyte MPs was
performed using anti-CD61, anti-CD45, anti-Ter-119/erythroid
cell and anti-CD133 labeling, respectively. Irrelevant mouse IgG
was used as an isotype-matched negative control for each sample.
For numeration studies, 8 mL of PFP were incubated with either
1 mL of specific antibody (BioLegend, San Diego, CA). After 45
minutes of incubation at room temperature, samples were diluted
in 300 mL of 0.9% saline salt solution. Annexin V (BioVision Inc.,
Mountain View, CA) binding was used to numerate phosphati-
dylserine-expressing circulating MPs (2 mL of annexin V/5 mL
PFP). Then, in order to enumerate MPs, an equal volume of
sample and Flowcount beads were added and samples were
analyzed in a flow cytometer 500 MPL system (Beckman Coulter,
Roissy, France) as previously described [46,47].
Isolation, culture and characterization of EPCs
Bone marrow-derived cells were obtained by isolating mono-
nuclear cells from bone marrow of WT or KO mice (6 to 8 week
old) using HistopaqueH 1077 (Sigma-Aldrich, St Louis, MO)
density-gradient centrifugation. Briefly, immediately after isola-
tion, total mononuclear cells (10
6 cells/cm
2) were plated on culture
dishes coated with (10 mg/mL) fibronectin (BD Biosciences, San
Jose, CA) and maintained in EGM-2 endothelial medium
BulletKit system (Lonza, Walkersville, MD) consisting of endo-
thelial basal medium supplemented with 5% FBS, VEGF, FGF-2,
EGF, IGF-1, ascorbic acid, gentamicin sulfate amphotericin,
hydrocortisone and heparin. After 24 h, non-adherent cells were
removed by washing with PBS, and adherent cells were cultured in
EGM-2 endothelial medium in the presence of either washing
medium, MPs from WT (MPs
PPARa+/+) or KO (MPs
PPARa2/2)
mice, for the whole culture period (7 days). Cells were treated at
circulating levels of MPs detected in the blood of mice as
previously performed [46,47]. In another set of experiments, the
specific agonist PPARa, WY-14643 (Calbiochem, London, UK;
5 mM) was used to activate PPARa in bone marrow-derived cells
either from WT or KO mice. To analyze cell phenotype, extensive
characterization of isolated cells at day 0 and after 7 days of
MPs-PPAR & Endothelial Cells
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cytometry using the following Abs: anti-CD133-FITC
(eBioscience, San Diego, CA), anti-CD14-FITC (BioLegend, San
Diego, CA), anti-Ly-6A/E (Sca-1)-PE/Cy7, anti-Flk-1 (VEGFR2)-
PE, or anti-F4/80-PE/Cy7, anti-CD45-PE/Cy5 (BioLegend),
anti-CD31 (BD Biosciences, San Jose ´, CA) followed by incubation
with goat anti-rat IgG-FITC (Southern Biotech, Birmingham,
AL).
After 7 days of treatment with MPs, adherent EPCs were
characterized by confocal microscopy and by flow cytometry.
Briefly, adherent cells were incubated with 2.5 mg/mL 1,
19-dioctadecyl-3,3,39,39-tetramethyl-indocarbocyanine-labeled
acetylated-LDL (DiI-Ac-LDL) (Harbor Bioproducts, Norwood,
MA) for 3 hours and then, fixed with 2% paraformaldehyde
and counterstained with 10 mg/mL FITC-labeled lectin from
Bandeiraea simplicifolia (Sigma-Aldrich) for 1 hour at 37uC.
Nuclei were counterstained with 49,6-diamidino-2-phenylin-
dole (DAPI) (Santa Cruz Biotechnology, Santa Cruz, CA) at
room temperature for 5 min. Double positive cells (DiI-ac-
LDL
+/FITC-lectin
+), identified as EPCs by confocal micros-
copy and by three independent investigators, were counted in
5 randomly selected high-magnification fields of each culture
slide by using a computer-based program.
In parallel, after 7 days of treatment, adherent cells were
detached with scratching with accutase (Sigma-Aldrich), and then
incubated for 45 minutes at room temperature simultaneously
with anti-Ly-6A/E (Sca-1)-PE/Cy7 and anti-Flk-1-PE Abs or anti-
F4/80-PE/Cy7 and anti-CD31 followed incubation with goat
anti-rat IgG-FITC. Isotype-matched antibodies served as controls.
After washing, cells were analyzed by flow cytometer 500 MPL
system (Beckman Coulter). Ten thousand events were acquired by
sample.
Aortic EC isolation and characterization
Aortic ECswere isolatedfrom eitherPPARa+/+ orPPARa2/2
mice (6 to 8 week old) as previously described [48]. The endothelial
phenotype of primary aortic ECs was verified by flow cytometry
(data not shown).
In vitro capillary network formation on MatrigelH
ECs isolated from either PPARa+/+ or PPARa2/2 aorta
were seeded (10
5 cells/cm
2) on culture dishes coated with
extracellular matrix gel from Engelbreth-Holm-Swarm murine
sarcoma (MatrigelH, Sigma-Aldrich). Briefly, 200 mL of MatrigelH
substrate diluted with serum-free medium (1:1 dilution) was added
into a four-well plate and allowed to solidify for 1 hour at 37uC.
Then, cells were incubated with medium containing 5% of FBS
and allowed to adhere for 1 hour. ECs were incubated for 24 hour
in the absence or in the presence of MPs from either PPARa+/+
or PPARa2/2 mice. Capillary-like structures formation was
examined using an inverted phase contrast microscope (MOTIC
AE21) and quantified using ImageJ software.
In vivo MatrigelH plug assay
For in vivo studies of bone marrow-derived cell-induced
angiogenesis, isolated bone marrow-derived cells from WT mice
were incubated in the absence or in the presence of MPs isolated
from PPARa+/+ or PPARa2/2 mice for 7 or 15 days. MatrigelH
plugs were prepared on ice by mixing 500 mL of MatrigelH
(Sigma-Aldrich) with recombinant bFGF (300 ng/mL, Peprotech,
Rocky Hill, NJ) and bone marrow-derived cells treated or
untreated with MPs. This mixture was injected subcutaneously
on the back of WT mice. At day 7, MatrigelH plugs were removed
and homogenized in lysis buffer and incubated for 24 hour at 4uC
and then, disrupted with a Polytron (PRO250, Monroe, CT).
Hemoglobin concentration was measured in the supernatants with
Drabkin’s reagent (Sigma-Aldrich) according to the manufactur-
er’s instructions.
Quantitative-PCR (q-PCR) analysis
Bone marrow-derived cells isolated from PPARa+/+ mice were
grown for 7 days in the absence or presence of MPs isolated from
PPARa+/+ or PPARa2/2 mice. Cells were washed with PBS
and lysed with Tri-reagent lysis buffer. Cell lysates were frozen in
liquid N2 and used to investigate the expression of mRNA for 52
transcripts related to differentiation and angiogenesis by quanti-
tative real-time reverse transcription-polymerase chain reaction
(q-PCR) (Table S1). q-PCR analyses were carried out by Service
Commun de Cytome ´trie et d’Analyses Nucle ´otidiques from
Angers University, using a Chromo 4
TM (Bio-Rad, Hercules, CA)
and SYBR Green detection. Primers were designed using Primer3
software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.
cgi). Quantifications were realized according to the DCt method
and the relative gene expression levels were normalized using the
geometric mean of three housekeeping genes as previously
described [49].
Western blot
Adherent cells were homogenized and lysed. Proteins (20 mg)
were separated on 10% SDS-PAGE. Blots were probed with anti-
endothelial NOS (eNOS), (BD Biosciences), ICAM-1, VEGF and
fms-like tyrosine kinase (FLT-1) (Santa Cruz Biotechnology),
phosphorylated (Ser32/36)-I-kBa, (US Biological, Swampscott,
MA), Akt, Phospho-Akt (ser473), (Cell signaling, Beverly, MA)
Abs. A monoclonal mouse anti-b-actin Ab (Sigma-Aldrich) was
used at 1/2,000 dilution to visualize protein gel loading. The
membranes were then washed at least three times in Tris buffer
solution containing 0.05% Tween and incubated for 1 hour at
room temperature with the appropriate horseradish peroxidase
(HRP)-conjugated secondary antibody (Amersham Biosciences,
Piscataway, NJ). The protein-antibody complexes were detected
by ECL plus (Amersham) according to the protocol of the
manufacturer.
Data analysis
Data are represented as mean 6 SEM; n represents the number
of mice. Statistical analyses were performed by Mann-Whitney U-
tests (non-parametric) using Prism software package 4.00 (Graph-
PAD Software, San Diego, CA). P,0.05 was considered to be
statistically significant.
Supporting Information
Figure S1 Flow cytometry characterization of isolated cells
derived from bone marrow from PPARa+/+ mice at day 0 and
after 7 days of culture. At day 7, cells displaying a double labeling
for Sca-1/CD31, Sca-1/CD45, Sca-1/CD14 and F4/80/CD31
were significantly increased when compared to cells at day 0. Also,
Sca-1/Flk-1 and CD133/Flk-1 cells were slightly increased when
compared to cells at day 0. *P,0.05, **P,0.01, ***P,0.001 vs
isolated cells at day 0. Figure is representative of at least 6
independent experiments for each condition.
Found at: doi:10.1371/journal.pone.0012392.s001 (0.12 MB
TIF)
Figure S2 PPARa activation increased EPC differentiation.
(A) Western blot showing that, after 7 days of culture, EPCs
undergoing differentiation express PPARa. MPs treatment of
MPs-PPAR & Endothelial Cells
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indicating that of PPARa transfer did not take place. Protein
expression was normalized by b-actin. (B) Flow cytometric analysis
of EPC differentiation showed that PPARa activation (treatment
of EPCs isolated from WT mice with WY-14643 (5 mM), a specific
PPARa agonist) increased significantly Sca-1+/Flk-1+ cells
indicating an increased differentiation. (C) Treatment of EPCs
isolated from PPARa2/2 with PPARa agonist had no effect on
EPC differentiation in vitro. (D) Sca-1+/Flk-1+ percentage of cells
isolated from PPARa2/2 was not modified in the presence of
MPsPPARa+/+.* P ,0.05 vs untreated cells. Figures are repre-
sentative of at least 3 independent experiments for each condition.
Found at: doi:10.1371/journal.pone.0012392.s002 (0.18 MB
TIF)
Figure S3 Organization of ECs into capillary-like structures on
MatrigelH wasnotimpaired inECsisolatedfromPPARa2/2mice.
(A) Phase contrast micrographs of aortic ECs isolated from
PPARa2/2 and their corresponding WT mice. ECs were grown
for 24 hours on Matrigel matrix. (B) Quantification of capillary
number revealed that there was no significative difference in the
number of formed capillary-like structures on MatrigelH between
PPARa2/2 and their corresponding WT mice. Figures are
representative of at least 4 independent experiments for each
condition.
Found at: doi:10.1371/journal.pone.0012392.s003 (0.71 MB
TIF)
Table S1 Genes analyzed by qRT-PCR.
Found at: doi:10.1371/journal.pone.0012392.s004 (0.03 MB
DOC)
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